Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
Oncolytics Biotech Q1 EPS $(0.12) Misses $(0.11) Estimate
Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 20 percent decrease over losses of $(0.10) per share from
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
A Preview Of Oncolytics Biotech’s Earnings
Oncolytics Biotech (NASDAQ:ONCY) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Oncolytics Biotech will report an earnings per share (EPS) of $-0.11.
Oncolytics Biotech Announces Publication Of Preclinical Data Demonstrating The Synergistic Anti-Cancer Activity Of Pelareorep Combined With CAR T Cell Therapy In Solid Tumors In Science Translational Medicine
- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors
- Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a
Recap: Oncolytics Biotech Q4 Earnings
Oncolytics Biotech (NASDAQ:ONCY) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell
• Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: